JOINEXPO Exhibition Construction Company
In the wave of precision medicine, Ruilaipu (Hangzhou) Medical Technology Co., Ltd. (hereinafter referred to as “Ruilaipu Medical”) takes innovation as the sail and technology as the rudder, becoming an innovative force in the global medical mass spectrometry field. As a national high-tech enterprise, the company has been focusing on the research and application of clinical mass spectrometry detection technology since its establishment in 2019. It is committed to empowering precise diagnosis with cutting-edge technology and providing intelligent solutions for the global medical industry.
Design and Construction Site Map of China International Laboratory Medicine and Blood Transfusion Instrument Reagent Expo, Keywords: Exhibition Design and Construction Company
1、 Leading technology, defining industry benchmarks
Ruilaipu Medical has gathered more than 160 industry elites (with a research and development team accounting for over 60%), relying on core technologies with independent intellectual property rights, to create two core product matrices: high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) detection system and fully automated sample pretreatment platform.
1. The product has passed ISO 13485 international certification, covering clinical scenarios such as newborn screening, drug concentration monitoring, and metabolomics analysis with ultra-high sensitivity, stability, and automation level, helping medical institutions achieve dual breakthroughs in detection efficiency and accuracy.
2. Innovative achievements have been frequently recognized: winning honors such as the “First Equipment Set in Zhejiang Province” and the German Red Dot Design Award, demonstrating the hard core strength of “Made in China”.
2、 Empowering with wisdom, driving industry transformation
Ruileipu Medical’s mission is to make precise diagnosis within reach, breaking the limitations of traditional detection technology
1. Through full process automation and AI intelligent analysis, the operational threshold is significantly reduced, the standardization level of testing is improved, and grassroots medical institutions are empowered;
2. Collaborate with multiple tertiary hospitals and research institutions to promote the clinical implementation of mass spectrometry technology, serving over 500 clients worldwide, covering key areas such as disease early screening and personalized medication guidance.
3、 Capital favors, creating a blueprint for the future together
The company has completed multiple rounds of billion yuan level financing with technological barriers and market potential, attracting top investment institutions to continue to increase their investment. In the future, Ruilai Pu Medical will continue to deepen its research and development of mass spectrometry technology, expand new scenarios such as early diagnosis and precision treatment of tumors, accelerate its global layout, and jointly build an open and collaborative medical ecosystem with partners.
4、 Join Ruilaipu and embark on a new era of precision medicine together
Whether you are a medical institution, research institution, or industry investor, Ruilaipu Medical sincerely invites you to join hands and redefine the boundaries of diagnosis with innovative technology, so that more lives can benefit from precision.
